Categories: News

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

Staff

Recent Posts

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…

2 hours ago

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…

2 hours ago

ForeSee Medical and Vim Announce Strategic Partnership to Enhance Risk Adjustment and Streamline Provider Workflows

SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…

2 hours ago

ForeSee Medical and Vim Announce Strategic Partnership to Enhance Risk Adjustment and Streamline Provider Workflows

SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…

3 hours ago

Butterfly Network’s RoHS Lead Exemption Revocation Request Progresses to Stakeholder and Consultant Assessment

Oeko-Institut appointed for third-party evaluation; stakeholder consultation will run June 6, 2025 - August 1,…

3 hours ago

Ambio Life Sciences Launches World’s First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions

Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized…

3 hours ago